Welcome to our dedicated page for Appili Ther news (Ticker: APLIF), a resource for investors and traders seeking the latest updates and insights on Appili Ther stock.
News about Appili Therapeutics Inc. (APLIF) focuses on its progress as an infectious disease biopharmaceutical company developing anti-infective therapies and medical countermeasures. Company updates highlight commercial performance of its FDA-approved metronidazole oral suspension LIKMEZ, advancement of its tularemia vaccine candidate ATI-1701, development of the topical antiparasitic ATI-1801 for cutaneous leishmaniasis, and its collaboration with Vitalex Biosciences on the fungal vaccine program VXV-01.
Investors and observers following Appili’s news can track announcements on government contracts and grants, including cooperative agreements with the U.S. Air Force Academy and a NIAID contract valued at up to US$40 million for VXV-01. Releases also describe multiple additional U.S. federal funding proposals that could support manufacturing, nonclinical and preclinical studies, regulatory work, IND submissions, and Phase 1 clinical trials across the company’s pipeline.
Regular news items include financial and operational results, scientific publications in peer-reviewed journals, and presentations at sector events such as the NATO Chemical, Biological, Radiological and Nuclear Conference, the BARDA Innovation Symposium, and biodefense consortium meetings. These updates provide context on ATI-1701’s preclinical data, ATI-1801’s regulatory interactions with the FDA, and LIKMEZ patent developments and commercialization activities.
By reviewing Appili Therapeutics news on this page, readers can follow how the company’s infectious disease and biodefense programs evolve over time, how non-dilutive government funding contributes to its development plans, and how its commercial and pipeline assets may influence the outlook for APLIF stock.
Appili Therapeutics (TSX:APLI; OTC:APLIF) reported Q3 FY2026 results ending Dec 31, 2025, highlighting a US$40 million NIAID award for VXV-01 and US$82 million in proposals under review. The company recorded a quarterly net loss of CAD$1.0 million and CAD$0.2M cash on hand as of Dec 31, 2025.
Appili cited commercial momentum for LIKMEZ (ATI-1501), GMP manufacture for ATI-1701, and a defined FDA pathway for ATI-1801 with potential PRV eligibility.
Appili Therapeutics (OTCPink: APLIF) reported Q2 fiscal 2026 results for the quarter ended Sept 30, 2025, highlighting a new NIAID contract worth up to US$40 million for VXV-01 and US$90 million in pending funding proposals across infectious disease programs.
The company reported a net loss of $1.0 million for the quarter and held $0.3 million cash at Sept 30, 2025. Appili also noted >US$66 million previously secured in government contracts and commercial momentum from the U.S. re-launch of LIKMEZ® (metronidazole oral suspension).
Appili Therapeutics (OTC: APLIF) will attend the BARDA Innovation Symposium on November 20, 2025 in Washington, D.C., highlighting its government-funded biodefense pipeline.
Key facts: Appili and partner Vitalex received a up to US $40 million NIAID contract for VXV-01 (five-year award with a $3.6M base and up to $36.3M in options). The company also submitted U.S. federal proposals totaling US $94M in potential awards and has secured over US $66M in government contracts and grants to date.
Appili Therapeutics (OTC:APLIF) and Vitalex Biosciences have secured a significant US$40 million contract from NIAID to develop VXV-01, a novel fungal vaccine. The contract includes a base period of US$3.6 million for vaccine manufacturing and additional options worth US$36.3 million to support development through Phase 1 trials.
VXV-01 is a dual-antigen vaccine targeting surface antigens of pathogenic fungi, specifically designed to combat invasive fungal infections caused by Candida species. With global fungal infections affecting 6.5 million people annually and causing approximately 3.8 million deaths, this development represents a potential breakthrough as no fungal vaccines are currently approved for human use.
The collaboration leverages Appili's expertise in vaccine development and government contracting alongside Vitalex's research capabilities to advance this promising candidate through IND submission and Phase 1 clinical trials.Appili Therapeutics (OTCPink: APLIF), a biopharmaceutical company specializing in infectious diseases and biodefense drug development, held its annual and special meeting of shareholders with all proposed resolutions receiving approval.
The shareholders elected six directors to the board with overwhelming support, each receiving over 99% approval: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni, and Prakash Gowd. Additionally, shareholders approved the reappointment of PricewaterhouseCoopers as auditors, and endorsed the company's rolling 10% stock option plan and equity incentive plan.
Appili Therapeutics (OTC:APLIF) announced its participation in the NATO Chemical, Biological, Radiological and Nuclear Conference in Switzerland. Dr. Carl Gelhaus, Director of Non-Clinical Research, will present updates on ATI-1701, the company's first-in-class vaccine candidate for tularemia prevention.
The presentation will highlight preclinical data for ATI-1701, which is being developed with support from the U.S. Air Force Academy. The vaccine aims to address a critical gap in NATO's biodefense capabilities against Francisella tularensis, a highly infectious pathogen considered a top-priority biothreat. Currently, NATO forces lack specialized tularemia vaccines that are available to adversarial militaries.
Appili Therapeutics (OTC:APLIF), a biopharmaceutical company specializing in infectious diseases and medical countermeasures, reported its Q1 FY2026 financial results. The company has submitted seven U.S. government funding proposals totaling US$137 million and joined the U.S. Medical CBRN Defense Consortium.
Key developments include: LIKMEZ® re-launch in the U.S. market, progress on ATI-1701 tularemia vaccine development with US$11.6 million in USAFA funding, and advancement of ATI-1801 for leishmaniasis treatment. The company reported a reduced net loss of $1.2 million compared to $1.6 million in the previous year, with cash position of $1.1 million as of June 30, 2025.
Appili Therapeutics (OTC:APLIF) has published significant findings in the journal Vaccine demonstrating the effectiveness of ATI-1701, their biodefense vaccine candidate against tularemia. The study showed 100% survival rates in rats challenged with aerosolized F. tularensis SCHU S4, even at doses exceeding 10,000 times the median lethal dose.
The vaccine demonstrated up to 100% protection in cynomolgus macaques, with reduced disease severity and improved outcomes. ATI-1701, being developed in partnership with the U.S. Department of Defense, represents a first-in-class vaccine candidate for tularemia prevention, addressing an unmet need as there are currently no approved vaccines in major global markets.
Appili Therapeutics (OTC:APLIF) reported its fiscal year 2025 results and operational updates. Key highlights include the successful re-launch of LIKMEZ™, their FDA-approved liquid metronidazole oral suspension, with commercial sales ongoing. The company has submitted five U.S. government proposals totaling up to US$125 million in potential funding.
The company reported a reduced net loss of $2.6 million ($0.02 per share) compared to $3.8 million in FY2024. Cash position improved to $1.2 million as of March 31, 2025. Progress continues on key programs including ATI-1701 (tularemia vaccine) under US$11.6M USAF funding and ATI-1801 for leishmaniasis treatment, which received positive FDA feedback for development strategy.
FAQ
What is the current stock price of Appili Ther (APLIF)?
What is the market cap of Appili Ther (APLIF)?
